372 related articles for article (PubMed ID: 18654925)
1. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
4. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
[TBL] [Abstract][Full Text] [Related]
5. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Neo-Sensitabs diffusion method for determining the antifungal susceptibilities of Cryptococcus gattii isolates, using three different agar media.
Pujol I; Pastor FJ; dos Santos Lazéra M; Guarro J
Rev Iberoam Micol; 2008 Dec; 25(4):215-20. PubMed ID: 19071889
[TBL] [Abstract][Full Text] [Related]
7. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
[TBL] [Abstract][Full Text] [Related]
8. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
9. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
10. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
11. [Genotypes and in vitro antifungal susceptibility of Cryptococcus isolates in Sichuan Province].
Lei Y; Xiao YL; He C; Zhang CY; Xie Y; Kang M
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Jan; 46(1):82-6. PubMed ID: 25807801
[TBL] [Abstract][Full Text] [Related]
12. Comparison of E-Test, disk diffusion and a modified CLSI broth microdilution (M 38-A) method for in vitro testing of itraconazole, fluconazole and voriconazole against dermatophytes.
Méndez CC; Serrano MC; Valverde A; Pemán J; Almeida C; Martín-Mazuelos E
Med Mycol; 2008 Mar; 46(2):119-23. PubMed ID: 18324490
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of Cryptococcus gattii clinical isolates.
Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
[TBL] [Abstract][Full Text] [Related]
14. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Fothergill A; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Sep; 43(9):4535-40. PubMed ID: 16145103
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories.
Dannaoui E; Paugam A; Develoux M; Chochillon C; Matheron J; Datry A; Bouges-Michel C; Bonnal C; Dromer F; Bretagne S
Clin Microbiol Infect; 2010 Jul; 16(7):863-9. PubMed ID: 19778296
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.
Espinel-Ingroff A; Canton E; Gibbs D; Wang A
J Clin Microbiol; 2007 Mar; 45(3):858-64. PubMed ID: 17215342
[TBL] [Abstract][Full Text] [Related]
17. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
Warnock DW; Johnson EM; Rogers TR
J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
Marco F; Pfaller MA; Messer S; Jones RN
Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
[TBL] [Abstract][Full Text] [Related]
19. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
Guinea J; Peláez T; Alcalá L; Bouza E
Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
Swinne D; Watelle M; Nolard N
Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
